Zepbound vs Mounjaro in Special Populations: A Head-to-Head Clinical Comparison

Why Two Brand Names for One Drug?

Tirzepatide is a once-weekly injectable dual agonist acting at both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Eli Lilly brought it to market under two names because FDA approval pathways are indication-specific: Mounjaro earned type 2 diabetes approval in May 2022, and Zepbound earned chronic weight management approval in November 2023 [1].

The pen devices, concentrations, and dose escalation schedules are identical. A 10 mg Zepbound autoinjector and a 10 mg Mounjaro autoinjector deliver the same drug at the same dose. The clinical difference lies in which patients each product is covered for, which indication drives prior authorization, and which trial data anchor the prescribing decision for a given condition.

Why Indication Labels Matter Clinically

For patients with both obesity and type 2 diabetes, the prescriber must decide which indication to bill. Mounjaro gets prior-authorized under the diabetes benefit; Zepbound under the obesity benefit. Payers vary in which they cover, and some commercial plans cover neither for obesity as of mid-2025.

The GIP/GLP-1 Mechanism Distinction

Tirzepatide's dual receptor activity separates it from semaglutide (GLP-1 only). The GIP component appears to augment insulin secretion, reduce glucagon, and contribute to adipose tissue remodeling via direct GIP receptor signaling in adipocytes [2]. This dual mechanism is why weight-loss outcomes for tirzepatide exceed those of semaglutide 2.4 mg in indirect comparisons.

Patients With Type 2 Diabetes

Mounjaro is the labeled choice for patients with type 2 diabetes, and its trial package supports this fully. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg over 40 weeks. The 15 mg dose produced a mean A1C reduction of 2.01 percentage points versus 1.86 percentage points for semaglutide 1 mg (P<0.001), with 40% of tirzepatide 15 mg patients achieving A1C <5.7% [3].

Glycemic Outcomes by Dose

| Tirzepatide Dose | Mean A1C Reduction | Weight Loss | |---|---|---| | 5 mg | 1.87 pp | 7.6 kg | | 10 mg | 1.89 pp | 9.3 kg | | 15 mg | 2.01 pp | 11.2 kg | | Semaglutide 1 mg (comparator) | 1.86 pp | 5.7 kg |

Data from SURPASS-2 at 40 weeks [3].

Insulin-Naive vs Insulin-Using Patients

For insulin-naive patients on metformin, tirzepatide as an add-on produces superior glycemic and weight outcomes compared with basal insulin in the SURPASS-3 trial. Patients on background insulin face a heightened hypoglycemia risk when tirzepatide is added; dose reductions of sulfonylureas and insulin of 20 to 50% are often needed within the first 8 weeks.

The Zepbound Off-Label Question in T2D

Some patients with type 2 diabetes are prescribed Zepbound off-label when their diabetes plan does not cover Mounjaro but their obesity benefit covers Zepbound. The pharmacology is identical, but this creates documentation and billing complexity. The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm notes that weight-loss pharmacotherapy in patients with diabetes should be guided by both glycemic and cardiometabolic goals [4].

Patients With Obesity Without Diabetes

Zepbound carries the FDA approval for this population. SURMOUNT-1 (N=2,539) enrolled adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity who did not have type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight loss of 20.9% versus 3.1% for placebo (P<0.001) [5].

Dose-Response Relationship

The 5 mg dose produced 15.0% mean weight loss, and the 10 mg dose produced 19.5%, demonstrating a clear dose-response gradient. For patients who tolerate the titration, maximizing dose is associated with substantially greater weight loss.

Comorbidity Resolution

SURMOUNT-1 also tracked cardiometabolic markers. At 72 weeks, waist circumference fell by 14.0 cm in the 15 mg group, blood pressure decreased by 6.2 mmHg systolic, and fasting insulin improved meaningfully across all active arms [5]. These outcomes matter clinically for patients presenting with metabolic syndrome, sleep apnea, or nonalcoholic fatty liver disease alongside obesity.

SURMOUNT-OSA

A separate trial, SURMOUNT-OSA, examined tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. Published in 2024, it showed tirzepatide 10 or 15 mg reduced apnea-hypopnea index (AHI) by approximately 27 to 30 events per hour versus placebo, with 42% of patients in the treatment arm achieving an AHI below 5 events per hour [6]. This is now part of Zepbound's expanded FDA indication for sleep apnea approved in June 2024.

Patients With Chronic Kidney Disease

Neither Zepbound nor Mounjaro requires dose adjustment for any stage of CKD, including stage 4 and 5, per FDA labeling [1, 7]. Tirzepatide is metabolized via proteolytic degradation and does not depend on renal clearance for elimination.

Nausea Management in CKD

CKD patients often have baseline nausea and delayed gastric emptying. The standard 4-week titration intervals (starting at 2.5 mg weekly for 4 weeks, then increasing by 2.5 mg every 4 weeks) may need to be extended in CKD patients reporting persistent GI symptoms. Slower titration is clinically appropriate even though it is not mandated in the label.

Cardiovascular-Renal Overlap

The SURPASS-CVOT trial (tirzepatide vs insulin degludec in high-CV-risk T2D patients) reported that tirzepatide did not increase adverse renal outcomes and trended toward benefit on kidney function markers [8]. Formal nephrology guidelines have not yet incorporated tirzepatide-specific CKD recommendations as of mid-2025, but the CREDENCE and DECLARE data on GLP-1 receptor agonists as a class suggest a plausible renoprotective signal.

Patients With Established Cardiovascular Disease

The SELECT trial established semaglutide 2.4 mg as the first GLP-1 class agent with a CV outcomes trial showing reduced major adverse cardiovascular events (MACE) in adults with obesity and established CVD [9]. As of mid-2025, tirzepatide does not yet have a completed dedicated CV outcomes trial in the obesity-without-diabetes population.

SURPASS-CVOT Data

SURPASS-CVOT (N=12,101) enrolled adults with type 2 diabetes and high CV risk. Tirzepatide was non-inferior to insulin degludec on 3-point MACE (CV death, nonfatal MI, nonfatal stroke), with a hazard ratio of 0.85 (95% CI 0.71 to 1.02) [8]. Non-inferiority does not establish superiority, and the trial was not powered or designed to show a MACE reduction.

SURMOUNT-MMO

The SURMOUNT-MMO trial is the ongoing cardiovascular outcomes trial for Zepbound (tirzepatide) in adults with obesity and established CVD who do not have diabetes. Results are expected in 2026. Until those data publish, prescribers relying on SELECT data should note that semaglutide has the only available Class I cardiovascular outcomes evidence in the obesity-without-diabetes population [9].

Practical Prescribing in High-CV-Risk Patients

For patients with recent acute coronary syndrome (within 60 days), the GI side-effect profile of tirzepatide can mimic cardiac symptoms. Nausea, vomiting, and volume depletion from reduced oral intake may complicate hemodynamic assessment. Cardiologists and prescribing clinicians should coordinate if starting tirzepatide within 90 days of a cardiac event.

Older Adults (Age 65 and Older)

No pharmacokinetic dose adjustment is required for older adults based on age alone. Population PK modeling for tirzepatide found no clinically meaningful difference in drug exposure in patients aged 65 to 85 versus younger adults [1]. Three clinical considerations make tirzepatide management in this group distinct.

Sarcopenia and Lean Mass Loss

Weight loss from any GLP-1 or GIP/GLP-1 agent includes both fat mass and lean mass. In SURMOUNT-1, approximately 40% of total weight lost was lean mass in the tirzepatide arm, consistent with pharmacologically induced caloric restriction [5]. For older adults with existing sarcopenia or low muscle reserve, this is a meaningful concern. The standard clinical recommendation is resistance training three days per week and protein intake of 1.2 to 1.6 g/kg/day during active weight loss.

Fall Risk and Blood Pressure

Blood pressure reductions of 5 to 7 mmHg systolic observed in SURMOUNT-1 may be beneficial for most adults but can increase fall risk in older patients already on antihypertensives. A medication review for orthostatic hypotension risk is appropriate before initiating tirzepatide in adults over 75.

Swallowing and Injection Dexterity

The autoinjector design for both Zepbound and Mounjaro requires adequate hand strength and dexterity. Older adults with arthritis or reduced grip strength may need injection training with an in-office nurse or a caregiver-assisted administration plan.

Women Who Are Pregnant, Planning Pregnancy, or Postpartum

Both Zepbound and Mounjaro are contraindicated in pregnancy. Animal studies show fetal harm at clinically relevant exposures, and the FDA requires a Medication Guide for both products noting this risk [1, 7]. The labeled recommendation is to stop tirzepatide at least 1 month before a planned pregnancy, though some endocrinologists advise a 2-month washout given the accumulation kinetics of a weekly drug at steady state.

Fertility and PCOS

Women with polycystic ovary syndrome (PCOS) and obesity frequently cycle through fertility-adjacent prescribing. Significant weight loss of 10% or more of body weight can restore ovulatory function in anovulatory PCOS patients [10]. A woman who becomes ovulatory while on tirzepatide and is not using contraception faces an unplanned pregnancy risk. Prescribers should discuss contraception explicitly at every visit during active weight loss.

Postpartum Use

For postpartum women who are not breastfeeding, tirzepatide may be considered after the immediate postpartum period if indicated. Breastfeeding is a contraindication because no human data on transfer into breast milk exist, and animal data cannot rule out neonatal harm.

Patients Switching Between Zepbound and Mounjaro

Switching between brands is pharmacologically straightforward: the dose stays the same, the timing stays the same, and no re-titration is required if the patient has been stable on the equivalent dose of the other product.

When Switches Happen

Switches occur most often for three reasons. First, insurance changes mid-year that alter which brand is covered. Second, prior-authorization approval under a different indication (for example, a patient with both conditions gets Mounjaro approved via the diabetes benefit when Zepbound was previously covered via obesity). Third, manufacturer discount programs: Eli Lilly's savings card for Zepbound has at times been more accessible than the Mounjaro card for commercially insured patients without diabetes.

Clinical Protocol for a Same-Dose Switch

1. Confirm the last dose date and the dose in milligrams.
2. Write the new prescription at the same dose (not at 2.5 mg restart).
3. Instruct the patient to take the first dose of the new brand on the same day of the week they would have taken the previous brand.
4. No labs are required solely for the brand switch.

Re-Titration Scenarios

Re-titration from 2.5 mg is appropriate only if the patient has been off tirzepatide entirely for 6 or more weeks. GI tolerance returns to baseline after approximately 4 to 6 weeks off the drug, so resuming at the prior maintenance dose carries a higher nausea burden.

The AACE 2023 position on obesity pharmacotherapy states: "Dose escalation should be individualized based on tolerability and therapeutic response, and restarting at a low dose after prolonged discontinuation reduces adverse gastrointestinal effects" [4].

Patients With Hepatic Impairment

Mild, moderate, and severe hepatic impairment do not require dose adjustment for tirzepatide, per the FDA prescribing information [1, 7]. Population PK data show that hepatic impairment does not significantly alter tirzepatide exposure. For patients with nonalcoholic steatohepatitis (NASH) or metabolic-associated steatotic liver disease (MASLD), tirzepatide's weight loss effect appears to reduce hepatic fat fraction, though tirzepatide does not have an FDA indication for NASH as of mid-2025.

A 52-week placebo-controlled trial published in The Lancet in 2024 (N=190 patients with biopsy-confirmed MASH) found that tirzepatide 10 or 15 mg achieved MASH resolution without worsening fibrosis in 62.4% of treated patients versus 21.1% of placebo patients (P<0.001) [11]. This is an active area of regulatory review.

Adolescents and Pediatric Patients

Mounjaro is not FDA-approved for patients under 18. Zepbound is not FDA-approved for patients under 18 as of mid-2025. Eli Lilly has ongoing pediatric trials under the FDA Pediatric Research Equity Act. Off-label use in adolescents with severe obesity and comorbidities does occur but should be managed within a specialized pediatric obesity program with access to dietitian, behavioral, and endocrinology support.

Comparing Zepbound and Mounjaro: A Population-Level Summary

| Population | Preferred Brand | Key Trial | Key Caveat | |---|---|---|---| | T2D only | Mounjaro | SURPASS-2 | Monitor for hypoglycemia with SFU or insulin | | Obesity without T2D | Zepbound | SURMOUNT-1 | Insurance coverage variable | | Obesity with T2D | Either (payer-dependent) | SURPASS-2 / SURMOUNT-2 | Billing indication drives authorization | | CKD any stage | Either | SURPASS-CVOT | No dose adjustment needed | | CVD established | Either (no CV outcomes trial yet for tirzepatide in obesity) | SURPASS-CVOT (T2D) | SELECT data are for semaglutide, not tirzepatide | | Age ≥65 | Either | SURMOUNT-1 subgroup | Screen for sarcopenia, fall risk | | Pregnancy | Contraindicated | FDA label | Stop ≥1 month pre-conception | | MASH/NASH | Off-label Zepbound | Lancet 2024 MASH trial | Not FDA-approved for this indication | | Pediatric | Not approved | Ongoing trials | Specialist setting only |